Journal of Traditional Chinese Medicine >
Hemostatic mechanism of Jianpi Yiqi Shexue decoction (健脾益气摄血方) in treatment of immune thrombocytopenia
Received date: 2023-01-11
Accepted date: 2023-04-27
Online published: 2024-04-30
Supported by
National Key Basic Research and Development Program (973 Program) Project: the Therapeutic Mechanism and Pattern of Spleen Based Treatment for Thrombocytopenic Purpura Caused by Spleen Failure to Regulate Blood Flow(2013CB531705)
OBJECTIVE: To explore the early hemostatic mechanism of Jianpi Yiqi Shexue decoction (健脾益气摄血方, JYSD) in treating immune thrombocytopathy (ITP), based on the functional homeostasis of brain-intestine axis and blood neurotransmitter
METHODS: Non-drug treatment cases: Healthy volunteers were selected as normal control group and compared with patients with dysfunctional uterine bleeding, gastrointestinal tumors with bleeding and ITP, to detect the changes of blood 5-hydroxytryptamine (5-HT), β-endorphin (β-EP), vasoactive intestinal peptide (VIP) and compare the changes of blood neuro-transmitters in patients with different disease symptoms. Drug treatment cases: According to the randomized controlled multicenter clinical trial, 272 ITP patients were randomly divided into three groups: treatment group (JYSD) combined group (JYSD + Prednisone) control group (Prednisone). The changes of blood neuro-transmitter (5-HT, β-EP, VIP) before and after treatment were detected on the basis of peripheral blood platelet (PLT) and grade score.
RESULTS: Non-drug treatment cases: compared with the normal control group, the 5-HT level was higher, and the VIP and β-EP levels were both lower in the ITP group (P < 0.001), and the 5-HT, VIP and β-EP levels in the Gastrointestinal tumors with bleeding group were also lower compared with the normal control group (P < 0.05, 0.001). Drug treatment cases: The PLT grading scores of the combination group and the control group after treatment were lower than that before treatment (P < 0.05, 0.001). The PLT grading score of the 3 groups were compared in pairs after treatment: the combination group was the lowest among the 3 groups, which was better than the treatment group, but no better than the control group (vs the treatment group, P = 0.005, vs the control group, P = 0.709). The statistical results of full analysis set (FAS) and per protocol set (PPS) were consistent. The bleeding symptom scores of the treatment and combination groups began to drop 7 d after treatment, and kept dropping 14 d after treatment until the end of the study (P < 0.05). On the other hand, the control group started to show favorable results 14 d after treatment (P < 0.05). The FAS and PPS analysis results were consistent. In the control group, the 5-HT level was higher and VIP level was lower after treatment, compared with those before treatment (P < 0.05, 0.001). The β-EP levels were both increased in the treatment and combination group after treatment, compared with those before treatment (P < 0.05). After treatment, the β-EP levels in the treatment and control groups were significantly lower compared with the combination groups (P < 0.05). After treatment, compared with the control group, the VIP levels in the treatment and combination groups were up-regulated, and the differences were statistically significant by rank sum test (P < 0.01), and by t-test (P = 0.0002, 0.0001).
CONCLUSIONS: The prednisone tablet is better than the JYSD in increasing the level of PLT, while prednisone tablet combined with JYSD has more advantages in improving patients’ peripheral blood PLT levels. However, in improving the bleeding time of ITP patients, the combination of the two drugs was significantly delayed compared with the single usage, showing the characteristics and advantages of traditional Chinese medicine. JYSD can regulate the neurotransmitter level of ITP patients through the function of the brain-gut axis, mobilize 5-HT in the blood of ITP patients to promote the contraction of blood vessels and smooth muscles, and activate the coagulation mechanism are the early hemostatic mechanisms of JYSD. Up-regulate the levels of β-EP and balancing VIP levels may be an important part of the immune mechanism of JYSD for regulating ITP patients.
Ruibai LI , Ke CHEN , Wei MA , Yayue ZHANG , Li HOU , Xinyi CHEN . Hemostatic mechanism of Jianpi Yiqi Shexue decoction (健脾益气摄血方) in treatment of immune thrombocytopenia[J]. Journal of Traditional Chinese Medicine, 2024 , 44(3) : 537 -544 . DOI: 10.19852/j.cnki.jtcm.20240423.003
| 1. | Hemostasis and Thrombosis Group, Hematology Branch of Chinese Medical Association. Chinese expert consensus on the diagnosis and treatment of adult primary immune thrombocytopenia. Zhong Hua Xue Ye Xue Za Zhi 2016; 37: 89-93. |
| 2. | Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115: 168-86. |
| 3. | Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA. The American society of hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117: 4190-207. |
| 4. | Wang J, Zhang Y, Zhang L, et al. Clinical curative effect observation on treatment of immune thrombocytopenia treated with Jianpi Yiqi Shexue granules. Zhong Hua Zhong Yi Yao Za Zhi 2018; 33: 5700-4. |
| 5. | Zhang ZN, Shen D. Hematological diagnosis and efficacy standards. 3rd ed. Beijing: Science Press, 2007: 172-3. |
| 6. | Xie X, Gou WL. Obstetrics and gynecology. 8th ed. Beijing: Health Press, 2013: 180-5. |
| 7. | National Health and Family Planning Commission of the People's Republic of China. Standardized diagnosis and treatment guidelines for gastric cancer (trial). Zhong Guo Yi Xue Qian Yan Za Zhi (Dian Zi Ban) 2015; 18: 961-73. |
| 8. | National Health and Family Planning Commission Medical Administration Bureau; Chinese Medical Association Oncology Branch. Standards for diagnosis and treatment of colorectal cancer in China (2015 edition). Zhong Hua Wei Chang Wai Ke Za Zhi 2015; 18: 961-73. |
| 9. | Zheng XY. Guidelines for clinical research of new Chinese medicine. Beijing: China Medical Science and Technology Press, 2002: 167-8. |
| 10. | Chen ZL, Zhou YH. General situation of clinical research on treatment of immune thrombocytopenia with Traditional Chinese Medicine. Zhejiang Zhong Yi Za Zhi 2012; 47: 304-5. |
| 11. | Li YH, Bai YS. Overview of research on immune mechanism of Traditional Chinese Medicine intervention in primary immune thrombocytopenia. Shi Yong Zhong Yi Nei Ke Za Zhi 2015; 29: 166-8. |
| 12. | Wang MJ, Xu YG, Ding XQ, et al. Cellular immune function in patients with immune thrombocytopenia. Zhong Hua Lin Chuang Yi Shi Za Zhi 2018; 12: 65-9. |
| 13. | Chen K, Zhang YY, Zhao N, Ma W, Chen XY. Clinical study on the treatment of immune thrombocytopenia from the spleen based on changes in blood neurotransmitters. Beijing Zhong Yi Yao 2017; 36: 780-4. |
| 14. | Li HN, Ma YL, Zhang W, et al. Based on the theory of brain-gut axis to explore the mechanism of abdominal massage intervention in central nervous system diseases. Liaoning Zhong Yi Za Zhi 2019; 46: 2321-4. |
| 15. | Guo C, He P. Brain-gut axis and its research progress. Shi Jie Zui Xin Yi Xue Xin Xi Wen Zhai 2017; 17: 89-91. |
| 16. | Huang GZ, Zhang YD, He GB. The role of brain-gut axis in functional gastrointestinal disease and its research progress. Yi Xue Zong Shu 2013; 19: 447-5. |
| 17. | Sun B, Chen T, Wang T, Hu C, Zhu JC. Research progress on the interaction between intestinal flora and brain-gut axis. Zhong Guo Wei Sheng Tai Xue Za Zhi 2016; 28: 1206-11. |
| 18. | CHen YQ, Zhang C, Dong W, Yang XF. Molecular mechanism of neurotransmitter release. Zhong Guo Xi Bao Sheng Wu Xue Xue Bao 2019; 41: 33-41. |
| 19. | Guo XY, Yang XM, Ye T, Ji B, Feng J, Feng JL. Hydrogen sulfide: a new neuromodulator and protective agent of the central nervous system. Zhong Guo Nao Ke Ji Bing Yu Kang Fu Za Zhi 2016; 6: 60-4. |
| 20. | ZHou HY, Jiang HW, Wang MJ. Research progress of serotonin and its receptors. Shandong Yi Yao 2014; 54: 90-3. |
| 21. | Huang LY, Zhang EY, Gao B, Wu XJ, Wang ZT. Research progress on platelet signal transduction and related antiplatelet drugs. Zhong Guo Xin Yao Yu Lin Chuang Yao Li 2014; 25: 378-83. |
| 22. | Przyklenk K, Frelinger AL 3rd, Linden MD, et al. Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis. J Thromb Haemost 2010; 8: 331-40. |
| 23. | Moerland M, Kemme M, Dijkmans A, et al. Modulation of vasoactivity and platelet aggregation by selective 5-HT receptor antagonism in humans. J Cardiovasc Pharmacol 2011; 58: 575-80. |
| 24. | Wei W, Sui BD, Liu JW, Han L, Zhang B. The relationship between serotonin and the immune system and its role in immune-related disease. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2012; 28: 999-1001. |
| 25. | Wang S. Research progress in the clinical application of β-endorphin. Zhong Guo Zhong He Lin Chuang 2000; 16: 255-6. |
| 26. | He H, Xu Y, Zheng L, et al. Study on the effect of Jianpi Yiqi Shexue Fang on serum SIgA and β-EP in ITP model mice. Zhong Yi Yao Xin Xi 2015; 3: 47-9. |
| 27. | Huang C, Han LM. Electroacupuncture and immunity. Shandong Yi Yao 2012; 52: 91-2, 100. |
| 28. | Jia YM, Wang SR. The relationship between β-endorphin and the "spleen" of Traditional Chinese Medicine. Zhejiang Zhong Yi Yao Da Xue Xue Bao 2010; 34: 795-6. |
| 29. | Wu MY, Hu TM. Research progress of vasoactive intestinal peptide and digestive system diseases. Shi Jie Hua Ren Xiao Hua Za Zhi 2012; 20: 1453-7. |
| 30. | Cheng XW, Zheng QH, Li XL, Lin Z. Research progress on the intrinsic relationship between vasoactive intestinal peptides and certain gastrointestinal motility disorders. Zhong Guo Quan Ke Yi Xue 2012; 15: 237-41. |
| 31. | Chen XY, Chen YF. Research progress on the immunomodulatory effects of vasoactive intestinal peptides. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2012; 28: 1107-9. |
| 32. | Wang C, Li GH. Progress in the study of vasoactive intestinal peptides regulating lymphocyte differentiation. Mian Yi Xue Za Zhi 2010; 26: 275-7. |
| 33. | Cryan JF, O'Mahony SM. The microbiome-gut-brain axis: from bowel to behavior. Neurogastroenterol Motil 2011; 23: 187-92. |
| 34. | Gasbarrini A, Franceschi F, Tartaglione R, et al. Regression of autoimmune thrombocytopenia after eradication of H. pylori. Lancet 1998; 352: 878. |
| 35. | Sun LH, Meng YH, Hu J, Fan XH, Wang XL. The clinical significance of eradication of Helicobacter pylori in the treatment of idiopathic thrombocytopenic purpura. Xue Shuang Yu Zhi Xue Xue 2010; 16: 213-5. |
| 36. | Gao SH. Observation on the efficacy of eradication of Helicobacter pylori in the treatment of idiopathic thrombocytopenic purpura. Tianjin Yi Yao 2011; 39: 958-9. |
| 37. | Jin RR, Xi YM, Chao R, Chen C. Meta analysis of Helicobacter pylori eradication in the treatment of idiopathic thrombocytopenic purpura. Di San Jun Yi Da Xue Xue Bao 2011; 33: 1880-2. |
/
| 〈 |
|
〉 |